Cullen/Frost Bankers’s Coherus Oncology CHRS Stock Holding History

Cullen/Frost Bankers’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-23	Closed	–	–	1086
2022 Q1	$0	Hold	23	–	–	﹤0.01%	1170
2021 Q4	$0	Buy	+23	New	+$402	﹤0.01%	1205

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cullen/Frost Bankers's CHRS Position: Q2 2022 in Review

Cullen/Frost Bankers sold out of Coherus Oncology (CHRS) in Q2 2022, closing a stake of 23 shares.

Cullen/Frost Bankers first reported a position in CHRS in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 176 funds tracked by Wall St. Rank hold CHRS as of Q2 2022.

Cullen/Frost Bankers reported no remaining Coherus Oncology position as of Q2 2022 after selling out during the quarter.
Cullen/Frost Bankers sold 23 Coherus Oncology shares in Q2 2022.
Cullen/Frost Bankers first reported a position in Coherus Oncology in Q4 2021 and held it in 2 quarters.
Cullen/Frost Bankers's Coherus Oncology position peaked at $0 in Q1 2022.
176 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2022.

Based on Cullen/Frost Bankers's 13F filing for Q2 2022, filed 5 Aug 2022.